Nuvation Bio Inc.
General ticker "NUVB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.4B (TTM average)
Nuvation Bio Inc. follows the US Stock Market performance with the rate: 40.8%.
Estimated limits based on current volatility of 2.6%: low 4.72$, high 4.97$
Factors to consider:
- Total employees count: 220 as of 2024
- China accounted for 66.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Integration challenges, Labor/talent shortage/retention, Economic downturns and volatility, Cybersecurity threats
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.15$, 12.80$]
- 2026-12-31 to 2027-12-31 estimated range: [3.82$, 9.62$]
Financial Metrics affecting the NUVB estimates:
- Negative: with PPE of -15.3 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Industry operating income (median)
- Positive: Investing cash flow per share per price, % of 3.18 > -0.60
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
- Negative: 42.59 < Shareholder equity ratio, % of 51.40 <= 64.29
- Positive: Interest expense per share per price, % of 0.44 <= 0.73
Short-term NUVB quotes
Long-term NUVB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $7.87MM | $62.90MM |
| Operating Expenses | $99.82MM | $600.50MM | $275.97MM |
| Operating Income | $-99.82MM | $-592.63MM | $-213.06MM |
| Non-Operating Income | $24.02MM | $24.69MM | $8.44MM |
| Interest Expense | $0.00MM | $0.34MM | $13.68MM |
| R&D Expense | $71.29MM | $524.19MM | $115.11MM |
| Income(Loss) | $-75.80MM | $-567.94MM | $-204.63MM |
| Net Income(Loss)* | $-75.80MM | $-567.94MM | $-204.63MM |
| Stockholders Equity | $605.12MM | $463.79MM | $305.72MM |
| Inventory | $0.00MM | $0.00MM | $11.41MM |
| Assets | $621.48MM | $540.63MM | $594.82MM |
| Operating Cash Flow | $-68.00MM | $-130.41MM | $-173.43MM |
| Capital expenditure | $0.07MM | $0.16MM | $0.35MM |
| Investing Cash Flow | $8.92MM | $122.70MM | $99.52MM |
| Financing Cash Flow | $0.63MM | $0.33MM | $202.53MM |
| Earnings Per Share** | $-0.35 | $-2.11 | $-0.60 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.